IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI
- PMID: 16618584
- DOI: 10.1016/j.ijrobp.2005.12.046
IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI
Abstract
Purpose: To demonstrate the theoretical feasibility of integrating two functional prostate magnetic resonance imaging (MRI) techniques (dynamic contrast-enhanced MRI [DCE-MRI] and 1H-spectroscopic MRI [MRSI]) into inverse treatment planning for definition and potential irradiation of a dominant intraprostatic lesion (DIL) as a biologic target volume for high-dose intraprostatic boosting with intensity-modulated radiotherapy (IMRT).
Methods and materials: In 5 patients, four gold markers were implanted. An endorectal balloon was inserted for both CT and MRI. A DIL volume was defined by DCE-MRI and MRSI using different prostate cancer-specific physiologic (DCE-MRI) and metabolic (MRSI) parameters. CT-MRI registration was performed automatically by matching three-dimensional gold marker surface models with the iterative closest point method. DIL-IMRT plans, consisting of whole prostate irradiation to 70 Gy and a DIL boost to 90 Gy, and standard IMRT plans, in which the whole prostate was irradiated to 78 Gy were generated. The tumor control probability and rectal wall normal tissue complication probability were calculated and compared between the two IMRT approaches.
Results: Combined DCE-MRI and MRSI yielded a clearly defined single DIL volume (range, 1.1-6.5 cm3) in all patients. In this small, selected patient population, no differences in tumor control probability were found. A decrease in the rectal wall normal tissue complication probability was observed in favor of the DIL-IMRT plan versus the plan with IMRT to 78 Gy.
Conclusion: Combined DCE-MRI and MRSI functional image-guided high-dose intraprostatic DIL-IMRT planned as a boost to 90 Gy is theoretically feasible. The preliminary results have indicated that DIL-IMRT may improve the therapeutic ratio by decreasing the normal tissue complication probability with an unchanged tumor control probability. A larger patient population, with more variations in the number, size, and localization of the DIL, and a feasible mechanism for treatment implementation has to be studied to extend these preliminary tumor control and toxicity estimates.
Similar articles
-
Radiotherapy Boost for the Dominant Intraprostatic Cancer Lesion-A Systematic Review and Meta-Analysis.Clin Genitourin Cancer. 2016 Jun;14(3):189-97. doi: 10.1016/j.clgc.2015.12.005. Epub 2015 Dec 17. Clin Genitourin Cancer. 2016. PMID: 26768965 Review.
-
Pictorial review. Magnetic resonance for radiotherapy management and treatment planning in prostatic carcinoma.Br J Radiol. 2015 Oct;88(1054):20150507. doi: 10.1259/bjr.20150507. Epub 2015 Aug 17. Br J Radiol. 2015. PMID: 26279086 Free PMC article. Review.
-
Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1017-25. doi: 10.1016/j.ijrobp.2014.12.052. Int J Radiat Oncol Biol Phys. 2015. PMID: 25832692 Free PMC article.
-
Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions.Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):406-15. doi: 10.1016/j.ijrobp.2014.01.042. Epub 2014 Mar 28. Int J Radiat Oncol Biol Phys. 2014. PMID: 24685447 Free PMC article.
-
Effect on therapeutic ratio of planning a boosted radiotherapy dose to the dominant intraprostatic tumour lesion within the prostate based on multifunctional MR parameters.Br J Radiol. 2014 May;87(1037):20130813. doi: 10.1259/bjr.20130813. Epub 2014 Mar 6. Br J Radiol. 2014. PMID: 24601648 Free PMC article.
Cited by
-
Focal Boost in Prostate Cancer Radiotherapy: A Review of Planning Studies and Clinical Trials.Cancers (Basel). 2023 Oct 8;15(19):4888. doi: 10.3390/cancers15194888. Cancers (Basel). 2023. PMID: 37835581 Free PMC article. Review.
-
Introducing new plan evaluation indices for prostate dose painting IMRT plans based on apparent diffusion coefficient images.Radiat Oncol. 2022 Nov 23;17(1):193. doi: 10.1186/s13014-022-02163-7. Radiat Oncol. 2022. PMID: 36419067 Free PMC article.
-
Functional imaging-guided carbon ion irradiation with simultaneous integrated boost for localized prostate cancer: study protocol for a phase II randomized controlled clinical trial.Trials. 2022 Nov 8;23(1):934. doi: 10.1186/s13063-022-06798-5. Trials. 2022. PMID: 36348363 Free PMC article.
-
Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference.Front Oncol. 2021 May 14;11:652678. doi: 10.3389/fonc.2021.652678. eCollection 2021. Front Oncol. 2021. PMID: 34055621 Free PMC article.
-
Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294.Med Phys. 2021 Jul;48(7):e697-e732. doi: 10.1002/mp.14884. Epub 2021 May 20. Med Phys. 2021. PMID: 33864283 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical